文献速递甲状腺与浅表介入US

超声引导下射频消融治疗原发性甲状腺微小乳头状癌的临床结局

Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma.
PubMed 文献 · Clin Radiol · 2019-06-26

回顾性分析37例患者38个甲状腺微小乳头状癌结节接受20 W低功率超声引导射频消融的安全性和疗效。所有结节均完全消融,无并发症,甲状腺功能未受影响;中位随访6个月(范围1-18个月)时38个结节中37个完全吸收,全部37例患者无复发。作者认为低功率射频消融安全有效,可能成为手术和主动监测之外的替代治疗选择。

要点

  • 低功率20 W射频消融治疗甲状腺微小乳头状癌可实现完全消融,且无并发症。
  • 消融后结节体积逐渐缩小,12个月时平均体积降至0.01±0.03 ml,体积缩小率99.34±3.49%。
  • 中位随访6个月(范围1-18个月)时38个结节中37个完全吸收,37例患者均无复发。

核心结论

  • 低功率射频消融治疗甲状腺微小乳头状癌安全且疗效良好;除手术和主动监测外,射频消融可能成为这类患者的替代治疗选择。

研究设计与样本

  • 回顾性研究,纳入2014年9月至2017年12月接受超声引导射频消融(功率20 W)的37例患者共38个甲状腺微小乳头状癌结节;术前及术后1、3、6、12个月和之后每6个月评估影像学及甲状腺功能,计算结节体积和体积缩小率。

关键影像表现/征象

  • 消融后随访中结节体积逐渐缩小,12个月时平均体积降至0.01±0.03 ml,体积缩小率99.34±3.49%。
  • 中位随访6个月(范围1-18个月)时,38个结节中37个完全吸收,全部37例患者无复发。

诊断标准与关键数值

  • 所有38个结节均实现完全消融,无并发症发生,甲状腺功能未受影响。

临床应用与阅片要点

  • 作者认为,低功率射频消融可能成为甲状腺微小乳头状癌患者除手术和主动监测之外的替代治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate the safety, efficacy, and long-term outcomes of ultrasound-guided radiofrequency ablation (RFA) for the treatment of primary papillary thyroid microcarcinoma (PTMC).

MATERIALS AND METHODS: A total of 37 patients with 38 PTMC nodules underwent RFA at a power of 20 W between September 2014 and December 2017. The clinical data of these patients were reviewed retrospectively and analysed. Imaging studies of the nodules were conducted, and the patients' thyroid function was assessed before RFA; 1, 3, 6, and 12 months after RFA; and every 6 months thereafter. The volumes and volume reduction rate (VRR) of the nodules were also calculated.

RESULTS: RFA with a low power of 20 W was used in the treatment of 37 patients with 38 PTMC nodules. All nodules achieved complete ablation, no complications occurred, and thyroid function was not affected. During follow-up, the volume of the nodules gradually decreased. Twelve months after ablation, the mean volumes of the nodules significantly decreased to 0.01±0.03 ml with a VRR of 99.34±3.49%. At a median follow-up of 6 (range: 1-18) months, 37 of the 38 nodules were completely absorbed, and no recurrence was observed in all 37 patients.

CONCLUSIONS: Low-power RFA showed good safety and promising efficacy outcomes for the treatment of PTMC. In addition to surgery and active surveillance, RFA may be an alternative treatment option for patients with PTMC.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Ding M, Tang X, Cui D, et al. Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma. Clin Radiol. 2019. PMID: 31253420. doi:10.1016/j.crad.2019.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。